New Wegovy HD 7.2 mg: A New Option When Weight Loss Stalls/Plateaus

by Dr. Richard Lipman MD
Board Certified in Internal Medicine/Endocrinology

Wegovy 7.2 HD offers a new option in Wegovy weight-loss treatment. Many Wegovy-treated patients eventually reach the same stopping point: 2.4 mg once weekly, the previously highest approved injectable dose. Some of my patients continued to lose weight, but many eventually noticed that their appetite was returning, that weight loss was slowing, or that the scale had stopped moving altogether. They had developed a weight-loss plateau. Since the introduction of the 7.2 dose, we have been able to increase the dose and get off the plateaus with 3 new doses up to 7.2 mg!

New High Dose Wegovy 7.2 mg

A higher dose of Wegovy (semaglutide) has been approved by the FDA to provide greater weight-loss potential and improved appetite suppression, targeting individuals who may need more intensive support when weight loss slows or plateaus. The previous highest dose of Wegovy was 2.4 mg. Novo, the Danish manufacturer, has added a new Wegovy dose at 7.2 mg. This is called the Multi-Dose Wegovy Flex Touch 7.2 Pen. It is a great addition for individuals experiencing weight-loss plateaus on Wegovy.

Clinical trials, including the STEP UP study, indicated that a higher dose can lead to greater weight loss.

  • Increased efficacy: Research suggests a higher percentage of participants may achieve significant weight loss, with some achieving at least 25%. This is almost the same as what is seen with tirzepatides.
  • Potential Side Effects: The higher dose will not be right for everyone. Nausea, vomiting, constipation, abdominal discomfort, and other semaglutide-related effects remained important. Altered or uncomfortable skin sensations—called dysesthesia—were reported in 22% of patients taking 7.2 mg, compared with 6% taking 2.4 mg. Dose escalation should therefore be individualized rather than automatic.

  • Additional Weight Loss: In the 72-week STEP UP trial, average weight reduction with Wegovy HD was approximately 18.8%, compared with 15.5% with Wegovy 2.4 mg, when all randomized patients were included regardless of whether they remained on treatment. In an analysis estimating results among patients who stayed on treatment, the average loss was 20.7% with 7.2 mg versus 17.5% with 2.4 mg. About 31% of patients receiving 7.2 mg lost at least 25% of their starting weight, compared with approximately 15% receiving 2.4 mg.

    These averages may seem like only a few percentage points, but for a patient starting at 250 pounds, an additional 3% of body weight amounts to approximately 7½ pounds. Some patients experienced considerably more.

    Wegovy 7.2 HD marks a significant advancement in the treatment of GLP-1 disorders. It is the first instance in which a patient who is tolerating Wegovy but has stopped losing weight at a dose of 2.4 mg may not have exhausted all their options. Although the higher dose of 7.2 mg will not eliminate all plateaus, it could enable many patients to get off the plateau and continue losing weight without having to switch to another medication right away.

Determining if a Weight Loss Slowdown is a Plateau

The important point is to determine whether the plateaus are due to the medication not working well enough—or whether they instead need to be addressed through changes in diet, physical activity, sleep, other medications, or the overall treatment plan. In addition, patients on other medications might switch to Wegovy HD to restart their weight-loss program.

Obtaining Wegovy Doses between 2.4 mg and 7.2 mg Pens:

A blue Wegovy HD 7.2 mg dose conversion chart, with two side-by-side tables listing doses and U-100 units on a white background. A small notes box and fine-print instructions sit below, creating a clean clinical layout with crisp blue borders and headings.

fusion_builder_column]